Intelligence · Clinical Development
Pipeline search results
Programs matching “Vertex Pharmaceuticals” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 159 pipeline programs matching "Vertex Pharmaceuticals" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
TEZ/IVA
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
3 trials -
Telaprevir
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C, Chronic
2 trials -
Tezacaftor/Ivacaftor
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
3 trials -
VNZ/TEZ/D-IVA
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
4 trials -
VX-121/TEZ/D-IVA
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
6 trials -
VX-147
Vertex Pharmaceuticals (Australia) Pty.
Proteinuric Kidney Disease
1 trial -
VX-210
Vertex Pharmaceuticals (Australia) Pty.
Cervical Spinal Cord Injury
1 trial -
VX-445/TEZ/IVA
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
2 trials -
VX-509
Vertex Pharmaceuticals (Australia) Pty.
Rheumatoid Arthritis
3 trials -
VX-659/TEZ/IVA
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
4 trials -
VX-661 Plus Ivacaftor Combination
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
2 trials -
VX-661/Ivacaftor
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX-809
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
4 trials -
VX-880
Vertex Pharmaceuticals (Australia) Pty.
Diabetes Mellitus, Type 1
1 trial -
VX-880 solution for infusion
Vertex Pharmaceuticals (Australia) Pty.
Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia
1 trial -
VX20-121-104
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX20-445-112
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX21-121-105
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX21-147-301
Vertex Pharmaceuticals (Australia) Pty.
APOL1-mediated Proteinuric Kidney Disease (AMKD)
1 trial -
VX21-445-125
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial -
VX21-CTX001-141
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-Dependent-Thalassemia
1 trial -
VX21-CTX001-151
Vertex Pharmaceuticals (Australia) Pty.
Severe sickle cell disease (SCD)
1 trial -
VX21-CTX001-161
Vertex Pharmaceuticals (Australia) Pty.
Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)
1 trial -
VX22-445-122
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.